MX347632B - Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona. - Google Patents

Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona.

Info

Publication number
MX347632B
MX347632B MX2013001692A MX2013001692A MX347632B MX 347632 B MX347632 B MX 347632B MX 2013001692 A MX2013001692 A MX 2013001692A MX 2013001692 A MX2013001692 A MX 2013001692A MX 347632 B MX347632 B MX 347632B
Authority
MX
Mexico
Prior art keywords
oxazolo
pyrazine
dione
dihydro
pde
Prior art date
Application number
MX2013001692A
Other languages
English (en)
Other versions
MX2013001692A (es
Inventor
Franz Keppler Artur
Luiz Sacurai Sérgio
Eduardo Da Costa Touzarim Carlos
Henrique Zaim Márcio
De Nucci Gilberto
Original Assignee
Biolab Sanus Farmacêutica Ltda *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmacêutica Ltda * filed Critical Biolab Sanus Farmacêutica Ltda *
Publication of MX2013001692A publication Critical patent/MX2013001692A/es
Publication of MX347632B publication Critical patent/MX347632B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D503/02—Preparation
    • C07D503/04—Preparation by forming the ring or condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describes una serie de derivados de 6, 7-dihidro-3H-oxazolo[3, 4-a]pirazin-5, 8-diona, sus mezclas, sus sales farmacéuticamente aceptables, que son inhibidores de PDE-5, que poseen propiedades vasodilatadoras y efectos de relajación. En particular, el derivado (R)-3-(1, 3-benzodioxol-5-il)-1-(1H-ind ol-3-il)-7-metil-6, 7-dihidro[1, 3joxazolo[3, 4-a]pirazin-5, 8-diona, su enantiómero (S)-3-(1, 3-benzodioxol-5-il)-1-(1 H-indol-3-il)-7-metil-6, 7-dihidro[1, 3]oxazolo[3,4-a]pirazin-5, 8-diona. La presente invención describe, además, procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen, así como usos como inhibidores de la enzima fosfodiesterasa de tipo 5 (PDE-5) en el tratamiento de te disfunción eréctil y trastornos tratables con inhibidor de PDE-5.
MX2013001692A 2010-08-13 2011-08-02 Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona. MX347632B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37348310P 2010-08-13 2010-08-13
PCT/BR2011/000255 WO2012019254A1 (en) 2010-08-13 2011-08-02 Derivatives of 6, 7-dihydro-3h-oxazolo [3, 4-a] pyrazine-5, 8- dione

Publications (2)

Publication Number Publication Date
MX2013001692A MX2013001692A (es) 2013-03-18
MX347632B true MX347632B (es) 2017-05-04

Family

ID=45023415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001692A MX347632B (es) 2010-08-13 2011-08-02 Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona.

Country Status (21)

Country Link
US (1) US8338432B2 (es)
EP (1) EP2603512B1 (es)
JP (1) JP5940535B2 (es)
KR (1) KR101871856B1 (es)
CN (1) CN103108878B (es)
AR (1) AR082661A1 (es)
BR (1) BR112013003225B1 (es)
CA (1) CA2807872C (es)
CL (1) CL2013000434A1 (es)
CO (1) CO6680703A2 (es)
DK (1) DK2603512T3 (es)
EC (1) ECSP13012486A (es)
ES (1) ES2565493T3 (es)
HK (1) HK1184786A1 (es)
HU (1) HUE027903T2 (es)
IL (1) IL224683A (es)
MX (1) MX347632B (es)
PL (1) PL2603512T3 (es)
RU (1) RU2581831C2 (es)
UY (1) UY33535A (es)
WO (1) WO2012019254A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
AR099523A1 (es) * 2014-02-24 2016-07-27 Biolab Sanus Farmacêutica Ltda Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona
MX2017003067A (es) * 2014-09-12 2017-06-14 Biolab Sanus Farmacêutica Ltda Nuevos compuestos derivados de piridopirimidinas.
KR20220035048A (ko) * 2019-07-15 2022-03-21 바이오랩 세너스 팔마씨우티카 엘티디에이. 화합물 3-(벤조[d][1,3]디옥솔-5-일)-7-(1-하이드록시프로판-2-일)-1-(1H-인돌-3-일)-6,7-디하이드로-3H-옥사졸[3,4-a]피라진-5,8-디온의 입체이성질체 및 항종양제 및 포스포디에스테라제 효소 억제제로서의 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026940A1 (fr) 1995-03-01 1996-09-06 Kyowa Hakko Kogyo Co., Ltd. Derives d'imidazoquinazoline
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
MXPA03011082A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Derivados de pirazino-1',2': 1,6-prirido-3,4-b-indol-1,4-diona.
DE60213798T2 (de) 2001-06-21 2007-08-16 Lilly Icos Llc, Wilmington Carbolinderivate als pdev inhibitoren
AR045950A1 (es) 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
RU2418590C2 (ru) * 2006-04-04 2011-05-20 Донг-А Фарматех Ко. Лтд. Средство для предупреждения и лечения гиперплазии предстательной железы, содержащее производное пиразолопиримидинона
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
WO2012019254A1 (en) 2012-02-16
CO6680703A2 (es) 2013-05-31
MX2013001692A (es) 2013-03-18
HUE027903T2 (hu) 2016-11-28
CA2807872A1 (en) 2012-02-16
CL2013000434A1 (es) 2013-06-07
JP2013533290A (ja) 2013-08-22
ES2565493T3 (es) 2016-04-05
AR082661A1 (es) 2012-12-26
KR20130109110A (ko) 2013-10-07
CN103108878A (zh) 2013-05-15
BR112013003225A2 (pt) 2016-06-07
EP2603512A4 (en) 2014-07-16
CN103108878B (zh) 2016-01-27
UY33535A (es) 2011-12-01
ECSP13012486A (es) 2013-04-30
IL224683A (en) 2016-03-31
KR101871856B1 (ko) 2018-06-28
RU2581831C2 (ru) 2016-04-20
RU2013110795A (ru) 2014-09-20
US8338432B2 (en) 2012-12-25
CA2807872C (en) 2018-07-24
JP5940535B2 (ja) 2016-06-29
EP2603512A1 (en) 2013-06-19
PL2603512T3 (pl) 2016-09-30
US20120040988A1 (en) 2012-02-16
EP2603512B1 (en) 2015-12-30
DK2603512T3 (en) 2016-04-04
HK1184786A1 (zh) 2014-01-30
BR112013003225B1 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
PH12018500944B1 (en) [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
MY160305A (en) Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
WO2011051342A8 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
PT2430022E (pt) Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
CL2008003577A1 (es) Compuestos derivados de imidazo[1,5-a] pirido[3,2-e]pirazina, 2, 6, 7, 9 tetrasustituidos; inhibidores de fosfodiesterasa 10; procedimiento de preparación; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades relacionadas con el sistema nervioso central, obesidad y trastornos del metabolismo.
MX2019005154A (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
IN2012DN01641A (es)
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
IN2012DN01642A (es)
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
MX2019005115A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Legal Events

Date Code Title Description
FG Grant or registration